Ewing's sarcoma (EWS) is the second most common primary malignant bone cancer in children. Advances in the treatment of EWS are desperately needed, particularly in the case of metastatic disease. A deeper understanding of collateral sensitivity, where the evolution of therapeutic resistance to one drug aligns with sensitivity to another drug, may improve our ability to effectively target this disease. For the first time in a solid tumor, we examine the repeatability of collateral sensitivity in EWS cell lines over time as evolutionary replicates evolve resistance to standard treatment. In doing so, we produced a temporal collateral sensitivity map that allows us to examine the evolution of collateral sensitivity and resistance in EWS. We found that the evolution of collateral sensitivity and resistance was predictable with some drugs, but had significant variation in response to other drugs. Samples that were most sensitive and most resistant to all drugs were compared using differential gene expression. Using this map of temporal collateral sensitivity in EWS, we can see that the path towards collateral sensitivity is not always repeatable, nor is there always a clear trajectory towards resistance or sensitivity. Identifying transcriptomic changes that accompany these states of transient collateral sensitivity could improve treatment planning for EWS patients. 2 50-70% 5-year survival rate, and metastatic disease has a devastating 18-30% 5-year survival rate. [2][3][4] Advances in the treatment 3 of EWS are desperately needed, particularly in the case of metastatic disease. Unfortunately, all recent attempts to improve 4 the chemotherapy regimen for EWS have only yielded modest results for non-metastatic cancer with little-to-no impact on 5 the course of metastatic disease. 3, 5 Researchers have tried adding ifosfamide and etoposide to standard EWS chemotherapy, 6 increasing the drug doses administered, and decreasing the interval between doses, all without meaningful improvement to 7 metastatic disease outcomes. 3, 5, 6 Even when treatment is initially successful, EWS often evolves therapeutic resistance, which 8 ultimately leads to disease relapse. 7 A deeper understanding of the evolutionary dynamics at play as EWS develops therapeutic 9 resistance may improve our ability to effectively target this disease.
Introduction
Ewing's sarcoma (EWS) is the second most common primary malignant bone cancer in children. 1, 2 Localized disease has a Overview of experimental evolution of resistance in Ewings sarcoma cell lines. As cells recovered from each exposure, cells were tested for their sensitivity for a panel of drugs and samples were frozen for potential use in RNA-sequencing. The drug dosage was only increased once throughout the experiment, at the fifth exposure to the VDC combination, described in Methods. Additionally, drug toxicity assays are performed at each time point to evaluate changes in therapeutic resistance or sensitivity over time. Although each cell line began with 5 experimental and 3 control evolutionary replicates, the A673 cell line lost one experimental replicate due to contamination. doxorubucin and etoposide over time, which is to be expected, because these two reagents are included in the treatment regimen.
127
Unexpectedly, most replicates acquired only mild resistance to cyclophosphamide, a drug which is included in both cycles of In many cases, it is clear that ranking samples by their change in drug response also ranks them based on how long they've 143 been exposed to the treatment regimen. Although this is not unexpected, interpreting the DE results in this context becomes 144 more difficult. Significant differences in gene expression may be related to a sample's chemosensitivity/chemoresistance, but 145 6/30 causation cannot be inferred, because these differentially expressed genes may simply be altered in response to continued 146 exposure to the treatment regimen. We chose to highlight the DE analyses where ranking samples in response to a given drug 147 didn't consistently arrange them in the order that they were isolated from the drug-cycling treatment. To that end, the waterfall 148 plots in Supplementary Figures 5-16 have darker sample labels (x-axis) depending on how long they've been exposed to the 149 treatment regimen (e.g. a sample label from the IE2 time point will be lighter than a sample from the IE3 time point). This 150 makes it easier to visualize whether the time points are well distributed in the log 2 fold change rankings.
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The right panel of Figure 4 demonstrates how samples were ranked based on their response to vorinostat (SAHA) and 152 SP-2509 (SP). Genes with significantly increased expression in a SAHA-resistant or SAHA-sensitive state are listed in Table 2 , 153 while genes with significantly increased expression in an SP-resistant or SP-sensitive state are listed in Table 3 . Table 3 . Genes with significant differential expression between SP-resistant and SP-sensitive samples. Differential gene expression analysis was performed using EBSeq in R, with maxround set to 15 and FDR of 0.05.
Genes with ↑ expression in SP-resistant state   ADGRL2  ANKS6  AP3B2  AP5Z1  ARHGEF9  C7  CAMKV  CCAR2  CD24  CDH4  CHGA  CORO7  CRMP1  DGCR8  DHCR7  DPP3  EPHA4  FASN  FOXO3B  FRG2FP  GALNS  HBA2  HDAC10  INCENP  INTS1  KSR1  LIN28B  LINC01089  LRCH2  MAN2C1  MEG3  MEG8  MRGPRF  MRNIP  MSRA  NEB  NEFM  NOM1  NUP210  PBX1  PC  PCBP2-OT1 PCDH17  PLXNB1  PPP1R1B  PRRC2B  PTPRG-AS1 PPYGO1  RNF130  RNF44  SBNO2  SCAMP4  SCARA3  SLC16A7  SLC29A2  SLITRK3  SYK  TAF15  TAF1C  TAF6L  TMEM271  TUBB3  VAX1  WDR17  WDR27  ZNF354C  ZNF414  ZNF667  ZNF667-AS1 ZNF675 ZNF730 ZNF736
Discussion
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In this work, we evolved two EWS cell lines, A673 and TTC466, with repeated exposure to standard-of-care chemotherapy in 156 order to investigate the evolution of collateral sensitivity and resistance through time. Each cell line was initially split into 8 Figure 2 shows that as the A673 experimental replicates were repeatedly exposed to the treatment regimen, states of 166 collateral sensitivity and resistance emerge consistently towards some drugs, while responses to other agents remain variable.
167
For example, despite no exposure to the drug, all replicates consistently moved to a state of collateral resistance towards Next, we see a greater number of differentially expressed genes when examining response to SP than SAHA. SP inhibits 191 lysine-specific demethylase 1 (LSD1, also known as KDMA1), which primarily acts as a histone demethylase. 23 Increased 192 expression of LSD1 has been implicated in many types of cancers (e.g. breast, prostate), and its targeted inhibition is being 193 investigated for therapeutic potential in EWS. 24 Due to the novelty of LSD1 inhibitors (including SP-2509), there is very
where S(X) is the expected response at dose X, a is the minimum response (when dose = 0), b is the highest response (when 286 dose = ∞), EC50 is the point of inflection (dose at which 50% of the response occurs), and H (known as the Hill slope) is the 287 steepest part of the curve. 29 A negative value for H, as seen in these models, denotes a descending curve, while a positive H 288 represents an ascending curve. Estimated EC50 from these models was solved using the ED function from the drc package The following plots mirror Figures 2 and 3 , respectively. The data does not censor the EC50 for Replicate 5 against olaparib 396 at the VDC5 timepoint, as seen in Figures 2 and 3 . Additionally, the drugs removed from main text analysis, vincristine, 397 pazopanib, and sodium thiosulfate are included. These drugs were censored in the main text due to poorly fit dose-response 398 models. Interpretation of these plots can be found in the main text. In Supplementary Figure 3 , we see that after the first exposure to the VDC drug combination (VDC1) in the TTC466 had been performed. In Supplementary Figure 3 , we see that after the second exposure to the EC combination (EC2), the EC50 415 of every experimental replicate has increased chemoresistance to olaparib before returning to a more sensitive state after the 416 next drug cycle. Supplementary Figure 4 , demonstrates that there is a large range in the control replicates at the corresponding 417 time point, which makes the comparison between the experimental and control replicates less reliable; however, it is clear that 418 from the time points before and after EC2, the EC50 increases significantly at EC2. 
